| Detection of circulating tumor necrosis factor after endotoxin administration HR Michie, KR Manogue, DR Spriggs, A Revhaug, S O'Dwyer, ... New England Journal of Medicine 318 (23), 1481-1486, 1988 | 2235 | 1988 |
| Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial ML Hensley, R Maki, E Venkatraman, G Geller, M Lovegren, ... Journal of Clinical Oncology 20 (12), 2824-2831, 2002 | 834 | 2002 |
| A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies C Aghajanian, S Soignet, DS Dizon, CS Pien, J Adams, PJ Elliott, ... Clinical cancer research 8 (8), 2505-2511, 2002 | 618 | 2002 |
| Increased tumor necrosis factor alpha mRNA after cellular exposure to ionizing radiation. DE Hallahan, DR Spriggs, MA Beckett, DW Kufe, RR Weichselbaum Proceedings of the National Academy of Sciences 86 (24), 10104-10107, 1989 | 556 | 1989 |
| Tumor necrosis factor and endotoxin induce similar metabolic responses in human beings. HR Michie, DR Spriggs, KR Manogue, ML Sherman, A Revhaug, ... Surgery 104 (2), 280-286, 1988 | 492 | 1988 |
| IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo M Koneru, TJ Purdon, D Spriggs, S Koneru, RJ Brentjens Oncoimmunology 4 (3), e994446, 2015 | 474 | 2015 |
| Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion. A phase I and pharmacologic study DR Spriggs, ML Sherman, H Michie, KA Arthur, K Imamura, D Wilmore, ... JNCI: Journal of the National Cancer Institute 80 (13), 1039-1044, 1988 | 416 | 1988 |
| Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment OO Yeku, TJ Purdon, M Koneru, D Spriggs, RJ Brentjens Scientific reports 7 (1), 10541, 2017 | 408 | 2017 |
| Circulating human peripheral blood granulocytes synthesize and secrete tumor necrosis factor alpha. DB Dubravec, DR Spriggs, JA Mannick, ML Rodrick Proceedings of the National Academy of Sciences 87 (17), 6758-6761, 1990 | 398 | 1990 |
| BRCA1 Up-Regulation Is Associated with Repair-mediated Resistance to cis-Diamminedichloroplatinum(II) A Husain, G He, ES Venkatraman, DR Spriggs Cancer research 58 (6), 1120-1123, 1998 | 380 | 1998 |
| Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients P Sabbatini, T Tsuji, L Ferran, E Ritter, C Sedrak, K Tuballes, ... Clinical cancer research 18 (23), 6497-6508, 2012 | 332 | 2012 |
| A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16ecto directed chimeric antigen receptors for recurrent ovarian cancer M Koneru, R O’Cearbhaill, S Pendharkar, DR Spriggs, RJ Brentjens Journal of translational medicine 13, 1-11, 2015 | 331 | 2015 |
| Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. D Fennelly, C Aghajanian, F Shapiro, C O'flaherty, M McKenzie, ... Journal of Clinical Oncology 15 (1), 187-192, 1997 | 306 | 1997 |
| Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: phase I toxicity and effects on lipid metabolism. ML Sherman, DR Spriggs, KA Arthur, K Imamura, E Frei 3rd, DW Kufe Journal of Clinical Oncology 6 (2), 344-350, 1988 | 298 | 1988 |
| Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma RA Soslow, G Han, KJ Park, K Garg, N Olvera, DR Spriggs, ND Kauff, ... Modern pathology 25 (4), 625-636, 2012 | 280 | 2012 |
| Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors AC Lockhart, ML Rothenberg, J Dupont, W Cooper, P Chevalier, ... Journal of Clinical Oncology 28 (2), 207-214, 2010 | 272 | 2010 |
| Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex: a phase I-II escalating dosage trial RT Schooley, TC Merigan, P Gaut, MS Hirsch, M Holodniy, T Flynn, S Liu, ... Annals of Internal Medicine 112 (4), 247-253, 1990 | 272 | 1990 |
| Adjuvant gemcitabine plus docetaxel for completely resected stages I–IV high grade uterine leiomyosarcoma: results of a prospective study ML Hensley, N Ishill, R Soslow, J Larkin, N Abu-Rustum, P Sabbatini, ... Gynecologic oncology 112 (3), 563-567, 2009 | 262 | 2009 |
| Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas X Zang, PS Sullivan, RA Soslow, R Waitz, VE Reuter, A Wilton, HT Thaler, ... Modern pathology 23 (8), 1104-1112, 2010 | 261 | 2010 |
| Tumor necrosis factor infusions have a procoagulant effect on the hemostatic mechanism of humans KA Bauer, H ten Cate, S Barzegar, DR Spriggs, ML Sherman, ... | 250 | 1989 |
